45.17
0.32 (0.71%)
| 前收盘价格 | 44.85 |
| 收盘价格 | 44.92 |
| 成交量 | 226,822 |
| 平均成交量 (3个月) | 472,421 |
| 市值 | 1,427,867,776 |
| 市盈率 (P/E TTM) | 27.71 |
| 预期市盈率 (P/E Forward) | 4.95 |
| 价格/销量 (P/S) | 1.90 |
| 股市价格/股市净资产 (P/B) | 3.92 |
| 52周波幅 | |
| 利润日期 | 26 Feb 2026 |
| 营业毛利率 | 6.61% |
| 营业利益率 (TTM) | 13.71% |
| 稀释每股收益 (EPS TTM) | 1.22 |
| 季度收入增长率 (YOY) | 22.70% |
| 季度盈利增长率 (YOY) | -91.30% |
| 总债务/股东权益 (D/E MRQ) | 411.94% |
| 流动比率 (MRQ) | 1.08 |
| 营业现金流 (OCF TTM) | 198.44 M |
| 杠杆自由现金流 (LFCF TTM) | 341.32 M |
| 资产报酬率 (ROA TTM) | 7.95% |
| 股东权益报酬率 (ROE TTM) | 19.23% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Collegium Pharmaceutical, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | -3.0 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.00 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 1.69% |
| 机构持股比例 | 117.12% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 60.00 (HC Wainwright & Co., 32.83%) | 购买 |
| 中 | 56.00 (23.98%) | |
| 低 | 54.00 (Needham, 19.55%) | 购买 |
| 平均值 | 56.67 (25.46%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 45.10 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 26 Feb 2026 | 54.00 (19.55%) | 购买 | 44.22 |
| 08 Jan 2026 | 56.00 (23.98%) | 购买 | 48.78 | |
| Barclays | 09 Jan 2026 | 56.00 (23.98%) | 购买 | 45.54 |
| HC Wainwright & Co. | 09 Jan 2026 | 60.00 (32.83%) | 购买 | 45.54 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| DREYER SCOTT | - | 39.99 | -49,976 | -1,998,540 |
| 累积净数量 | -49,976 | |||
| 累积净值 ($) | -1,998,540 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 39.99 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| DREYER SCOTT | 职员 | 03 Mar 2026 | 自动卖出 (-) | 49,976 | 39.99 | 1,998,540 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 15 Jan 2026 | 公告 | Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference |
| 08 Jan 2026 | 公告 | Collegium Provides 2026 Financial Guidance and Business Update |
| 30 Dec 2025 | 公告 | Collegium Announces the Closing of $980 Million Syndicated Credit Facility |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合